Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-RIMCEB
2009-016136-12Phase 3Completed
- Sponsor
- Kooperativní lymfomová skupina
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Kooperativní lymfomová skupina. Primary endpoint: Progression-free survival. Started Jan 2010; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2009-016136-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016136-12.